First Genesis Consulting
Contributor since: 2018
Company: Freelance Scientific Advisor/Consultant
Latest Articles
Can-Fite Biopharma And Namodenoson In NAFLD/NASH: A Targeted Therapeutic Approach
RedHill And Talicia: I Say Yes
RedHill Biopharma And RHB-104: It Takes Guts To Achieve Success
Intercept Pharmaceuticals And PSC: Primed To Profit
Durect In PSC: Is DUR-928 A Class Act?
Gilead In PBC: The Clinical Pursuit For Dominance
Genfit And PBC: Is Elafibranor A Contender?
CymaBay, GenKyoTex, And Intercept In PBC: The Clinical Differentiation
Conatus And Emricasan: The Moment
Allergan And Cenicriviroc In NASH Fibrosis: Revisiting FDA Guidelines For Conditional Approval
Viking Therapeutics And VK2809: The Hype On NASH
Aurinia And Voclosporin: Making A Difference In Focal Segmental Glomerulosclerosis
Pfizer And Conatus: Emricasan And NASH
Intercept And NASH: Itching To The Finish Line
Novartis And Conatus: A Strategic Anti-NASH Agenda
Bristol-Myers Squibb And NASH: Where Do We Stand?
Gilead And NASH: New Heydays Are Ahead
Corbus And Dermatomyositis: Lenabasum Is A Medical Marijuana Marvel
Conatus And Emricasan: The Countdown Begins
Genfit And Elafibranor In NASH Fibrosis: A Revisit Of The FDA Guidelines
Corbus And Inventiva In Systemic Sclerosis: It Takes Two
Gemphire And Gemcabene: Discerning The Scientific Facts On The FDA Hold
CymaBay And Inventiva: The Scientific Conversation On Seladelpar And Lanifibranor In NASH And PBC
Albireo And A4250: The Pediatric Remedy Making Waves
Conatus And Emricasan: Primed For Success
Allergan/Tobira And Cenicriviroc: The Overlooked And Misunderstood Immune Modulatory Anti-NASH Drug Candidate
Immune Pharmaceuticals And Bertilimumab: A Work In Progress
Intercept's Obeticholic Acid Therapy And NASH: The Scientific Truth Is That Every Cloud Has A Silver Lining
Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases
Lipotoxicity And Liver Diseases-NASH And PBC: Is Enanta A Player Or Spectator?
Novartis In Liver Diseases NASH And PBC: A Look At The Bright Side
Lipotoxicity And NASH: Gilead's Actions Speak Louder Than Words